INAB vs LIN · $18.4M cap vs P/E 34, rev $18.07B
In8bio Inc (INAB) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
In8bio Inc (INAB) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
INAB does not have a complete income-statement cache yet.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
INAB currently screens at market cap $18.4M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the INAB and LIN stock pages for the full models.
Not investment advice.